Results 171 to 180 of about 76,545 (327)

A Solution for Exosome‐Based Analysis: Surface‐Enhanced Raman Spectroscopy and Artificial Intelligence

open access: yesAdvanced Intelligent Discovery, EarlyView.
Exosomes are emerging as powerful biomarkers for disease diagnosis and monitoring. This review highlights the integration of surface‐enhanced Raman spectroscopy with artificial intelligence to enhance molecular fingerprinting of exosomes. Machine learning and deep learning techniques improve spectral interpretation, enabling accurate classification of ...
Munevver Akdeniz   +2 more
wiley   +1 more source

Machine Learning‐Assisted Infectious Disease Detection in Low‐Income Areas: Toward Rapid Triage of Dengue and Zika Virus Using Open‐Source Hardware

open access: yesAdvanced Intelligent Discovery, EarlyView.
This study introduces an affordable machine learning platform for simultaneous dengue and zika detection using fluorine‐doped tin oxide thin films modified with gold nanoparticles and DNA aptamers. Designed for low‐cost, hardware‐limited devices (< $25), the model achieves 95.3% accuracy and uses only 9.4 kB of RAM, demonstrating viability for resource‐
Marina Ribeiro Batistuti Sawazaki   +3 more
wiley   +1 more source

Study of Aptamer-Attached Juglone in Different pH Ranges and Ionic Concentrations of Buffers [PDF]

open access: green, 2012
Hossein Hamzeiy   +3 more
openalex  

Back Again to the Future: A New Era for Cerebroprotection

open access: yesAnnals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

DNA Aptamer Based Nanodrugs: Molecular Engineering for Efficiency

open access: green, 2015
Sena Cansız   +11 more
openalex   +1 more source

Skeletal Muscle Biomarkers of Amyotrophic Lateral Sclerosis: A Large‐Scale, Multi‐Cohort Proteomic Study

open access: yesAnnals of Neurology, EarlyView.
Objective Biomarkers with clear contexts of use are important tools for amyotrophic lateral sclerosis (ALS) therapy development. Understanding their longitudinal trajectory in the untreated state is key to their use as potential markers of pharmacodynamic response.
Oleksandr Dergai   +16 more
wiley   +1 more source

Site‐Selective Ligand Selection by Mutational Profiling for Covalent RNA Targeting

open access: yesAngewandte Chemie, EarlyView.
Using a mutational profiling approach an RNA‐targeted covalent probe was developed that is highly selective for the FMN riboswitch. The covalency was further supported by mass spectrometry experiments. The covalent probe selectively modifies the riboswitch at low micromolar concentrations within 10 min and remains functional when applied to an entire ...
Phillip Yesley   +3 more
wiley   +2 more sources

From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective The growing demand for personalized treatment in multiple sclerosis (MS) highlights the need for more precise biomarkers that can outperform magnetic resonance imaging and clinical assessment in patient stratification. Advances in multiplex proteomic technologies suggest that cerebrospinal fluid (CSF) analysis at MS onset may not only improve
Laura Ghezzi   +10 more
wiley   +1 more source

Growth, Dissolution and Segregation of Genetically Encoded RNA Droplets by Ribozyme Catalysis

open access: yesAngewandte Chemie, EarlyView.
Ribozymes enable sequence‐encoded turnover of RNA droplet material, resulting in transiently active droplets that selectively segregate based on their genotype. This establishes a direct link between genetic information and droplet behavior, marking a step toward programmable, evolvable RNA‐based compartments with life‐like properties.
Franziska Giessler   +5 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy